TMB is taken as a key driver in immunogenic neopeptides generation, which are displayed on MHC molecules on the tumor cell surface, and regulates the patient’s response to immune checkpoint inhibitors (ICIs). The gene discussed is HLA-C; the disease is neoplasm.